证券代码：301126 证券简称：达嘉维康 公告编号：2023-053 湖南达嘉维康医药产业股份有限公司 2023 年度以简易程序向特定对象发行股票摊薄即期回报的风险 提示及填补回报措施和相关主体承诺（修订稿） 本公司董事会及全体董事保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要提示： 本公告中公司对财务指标的假设分析不构成公司的盈利预测，为应对即期回 报被摊薄风险而制定的填补回报具体措施不等于对公司未来利润做出保证，投资 者不应据此进行投资决策，投资者据此进行投资决策造成损失的，公司不承担赔 偿责任。提请广大投资者注意。 湖南达嘉维康医药产业股份有限公司（以下简称"公司"）于 2023 年 4 月 28 日召开了第三届董事会第十九次会议和第三届监事会第十三次会议，审议通过了 公司 2023 年度以简易程序向特定对象发行股票方案的相关议案，本次发行完成 后，预计短期内公司基本每股收益、稀释每股收益将可能出现一定程度的下降， 公司短期内即期回报会出现一定程度摊薄。请广大投资者注意投资风险。 根据《国务院办公厅关于进一步加强资本市场中小投资者合法权益保护工作 的意见》（国办发[2 ...

证券代码：301126 证券简称：达嘉维康 1 公司本次以简易程序向特定对象发行股票募集资金总额为299,999,996.01元， 扣除发行费用后的募集资金净额将用于以下项目： 项目总投资金额高于本次募集资金使用金额部分由公司自筹解决；若本次 发行扣除发行费用后的实际募集资金净额低于拟投入的募集资金总额，不足部 分由公司自筹解决。在本次发行股票的募集资金到位之前，公司将根据项目需 要以自筹资金进行先期投入，并在募集资金到位之后，依照相关法律法规的要 求和程序对先期投入资金予以置换。 （一）连锁药店建设项目 本项目的投资总额为46,646.47万元，其中拟使用募集资金金额为21,000.00 万元，全部用于连锁药店建设项目。项目计划对公司现有的连锁药店业务进行 拓展，在海南、宁夏、安徽、山西共开设840家门店，以提高公司的业务覆盖规 模和服务能力，项目的建设期为3年。项目的实施有利于公司快速提高市场占有 率，增强盈利能力和综合竞争力。 （1）项目实施必要性 1）拓宽公司服务范围，满足不断增长的医药服务需要 近年来，在居民消费水平提高、人口老龄化、新一轮医药改革等因素的推 动下，我国医药市场持续扩容，带动药品流通 ...

证券代码：301126 证券简称：达嘉维康 1 湖南达嘉维康医药产业股份有限公司（以下简称"达嘉维康"、"公司"） 是在深圳证券交易所创业板上市的公司。为了满足业务发展的需要，进一步增 强资本实力及盈利能力，公司根据《中华人民共和国公司法》《中华人民共和 国证券法》《公司章程》和《上市公司证券发行注册管理办法》等有关法律、 法规和规范性文件的规定，拟以简易程序向特定对象发行股票（以下简称"本次 发行"），募集资金总额为299,999,996.01元，扣除发行费用后的募集资金净额将 用于连锁药店建设项目和补充流动资金。 （本报告中如无特别说明，相关用语具有与《湖南达嘉维康医药产业股份 有限公司2023年度以简易程序向特定对象发行股票预案》中相同的含义） 公司本次以简易程序向特定对象发行股票募集资金总额为299,999,996.01 元，扣除发行费用后的募集资金净额将用于以下项目： 单位：万元 | 项目名称 | 项目投资总额 | 募集资金拟投入金额 | | --- | --- | --- | | 连锁药店建设项目 | 46,646.47 | 21,000.00 | | 补充流动资金 | 9,000.00 | 9, ...

证券代码：301126 证券简称：达嘉维康 本公司及董事会全体成员保证本预案内容真实、准确、完整，并确认不存在虚假 记载、误导性陈述或重大遗漏，并对本预案内容的真实性、准确性、完整性承担个别 和连带的法律责任。 本预案按照《上市公司证券发行注册管理办法》等要求编制。 本次以简易程序向特定对象发行股票完成后，公司经营与收益的变化，由公司自 行负责；因本次以简易程序向特定对象发行股票引致的投资风险，由投资者自行负 责。 本预案是公司董事会对本次以简易程序向特定对象发行股票的说明，任何与之相 反的声明均属不实陈述。 投资者如有任何疑问，应咨询自己的股票经纪人、律师、专业会计师或其他专业 顾问。 本预案所述事项并不代表审批机关对于本次以简易程序向特定对象发行股票相关 事项的实质性判断、确认或批准，本预案所述本次以简易程序向特定对象发行股票相 关事项的生效和完成尚待取得有关审批机关的审核或批准。 若公司在本次发行的定价基准日至发行日期间发生派发股利、送红股或资本公积 金转增股本等除权、除息事项，本次发行价格下限将作相应调整。 4、根据本次发行的竞价结果，本次拟发行股票数量为27,548,209股，未超过发行 人董事会决 ...

证券代码：301126 证券简称：达嘉维康 公告编号：2023-050 湖南达嘉维康医药产业股份有限公司 关于持股5%以上股东减持比例达到1%的公告 股东宁波梅山保税港区量吉股权投资合伙企业（有限合伙）及其一致行动人宁波梅山保 税港区淳康股权投资合伙企业（有限合伙）保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 1. 量吉投资及其一致行动人淳康投资出具的《关于股份减持情况告知函》。 | A股 | 2,070,000 | | 1.00 | | | --- | --- | --- | --- | --- | | 合计 | 2,070,000 | | 1.00 | | | 通过证券交易所的集中交易 | 协议转让 | | | | | □通过证券交易所的大宗交易 | | | | | | □间接方式转让 | | | | | | □国有股行政划转或变更 | | | | | | □执行法院裁定 | | | | | | 本次权益变动方式（可多选） | 取得上市公司发行的新股 | | | | | □继承 | | | | | | □赠与 | | | | | | □表决权让渡 | | | | ...

证券代码：301126 证券简称：达嘉维康 湖南达嘉维康医药产业股份有限公司 3 .据2023年第一季度报告，公司报告期内营业收入8.77亿元， 同比增长39.72%，最主要原因有哪些?下一季度还能这样继续保持 吗? 答:您好，一季度盈利主要基于2022年公司不断收购德立信等 优质连锁药房标的，分销板块引入了新的分销项目，工业板块产品 也开始进入市场，为公司2023年一季度零售板块收入增长提供支 撑；公司持续多年深耕医药流通领域，长期积淀的品牌认可度及行 业积淀为公司不断引流新增业务。感谢您的提问。 商）协商确定。感谢您的提问。 4 .董秘您好，请问公司该如何进一步拓展产业链的上游? 2 .请问公司怎么解决增收不增利的问题？ 投资者关系活动记录表 答:您好，公司积极布局发展主业，近几年营业收入持续增 长。为扩大市场占有率及围绕主业布局，公司不断加大人员等方面 投入，并不断购置相关固定资产、无形资产等，前期布局投入一定 程度上在现阶段摊薄了公司的净利润水平。随着公司在零售药房及 医药工业板块的布局不断深化，将在后续为公司提供新的盈利支 撑，实现高质量发展。感谢您的提问。 编号：2023-001 | 投资者关系活 ...

证券代码：301126 证券简称：达嘉维康 公告编号：2023- 028 湖南达嘉维康医药产业股份有限公司 关于举办2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 湖南达嘉维康医药产业股份有限公司（以下简称"公司"）已于 2023 年 4 月 22 日在巨潮资讯网上披露了《2022 年年度报告》及《2022 年年度报告摘要》。 为便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司定 于 2023 年 05 月 09 日（星期二）15:00-16:00 在"价值在线"（www.ir-online.cn） 会议召开时间：2023 年 05 月 09 日（星期二）15:00-16:00 会议召开方式：网络互动方式 会议召开地点：价值在线（www.ir-online.cn） 会 议 问 题 征 集 ： 投 资 者 可 于 2023 年 05 月 09 日 前 访 问 网 址 https://eseb.cn/14eVAyttURy 或使用微信扫描下方小程序码进行会前提 问，公司将通过本次业绩说明会，在信息披露允许范围内就 ...

Financial Performance - The company's revenue for Q1 2023 was ¥876,697,159.06, representing a 39.72% increase compared to ¥627,481,511.98 in the same period last year[5] - Net profit attributable to shareholders decreased by 19.64% to ¥15,287,632.67 from ¥19,024,073.27 year-on-year[5] - Total operating revenue for Q1 2023 reached ¥876,697,159.06, an increase of 40% compared to ¥627,481,511.98 in the same period last year[22] - The net profit after deducting non-recurring gains and losses was ¥14,743,747.96, down 22.39% from ¥18,996,162.02 in the same period last year[5] - The net profit for Q1 2023 was CNY 18,898,654.75, a slight decrease from CNY 19,024,073.27 in Q1 2022, representing a decline of approximately 0.66%[24] - The total comprehensive income for Q1 2023 was CNY 18,898,654.75, slightly lower than CNY 19,024,073.27 in Q1 2022, reflecting a decrease of about 0.66%[25] - The operating profit for Q1 2023 was CNY 23,887,783.40, down from CNY 24,986,516.99 in the same period last year, reflecting a decrease of approximately 4.4%[24] Cash Flow and Liquidity - The net cash flow from operating activities improved by 65.75%, reaching -¥93,644,192.00, compared to -¥273,388,665.81 in the previous year[11] - The cash flow from operating activities showed a net outflow of CNY -93,644,192.00 in Q1 2023, an improvement from CNY -273,388,665.81 in Q1 2022[27] - The company's cash and cash equivalents decreased to ¥450,069,265.22 from ¥542,999,989.85 at the beginning of the year, a decline of approximately 17%[18] - The company reported a cash and cash equivalents balance of CNY 437,643,887.18 at the end of Q1 2023, down from CNY 465,103,994.99 at the end of Q1 2022[28] - The total cash inflow from financing activities in Q1 2023 was CNY 449,951,126.73, significantly higher than CNY 219,545,189.63 in Q1 2022, marking an increase of about 105%[27] - The company incurred a total cash outflow from investing activities of CNY 209,292,390.70 in Q1 2023, compared to CNY 13,487,863.80 in Q1 2022, indicating a substantial increase in investment expenditures[27] Assets and Liabilities - The total assets at the end of the reporting period increased by 6.92% to ¥4,203,580,541.74 from ¥3,931,417,218.63 at the end of the previous year[5] - The company's total assets reached ¥4,203,580,541.74, compared to ¥3,931,417,218.63 at the beginning of the year, reflecting a growth of about 6.9%[21] - Total liabilities increased to ¥2,357,970,678.47 from ¥2,113,011,215.54, a rise of approximately 11.6%[21] - Non-current assets totaled ¥1,139,835,964.67, up from ¥920,012,264.75, indicating a growth of about 23.9%[20] - Short-term borrowings increased to ¥1,326,629,126.56 from ¥1,198,109,033.37, reflecting a rise of approximately 10.7%[20] - Accounts receivable increased to ¥1,506,857,865.37 from ¥1,399,682,875.49, representing a growth of about 7.7%[18] - Inventory rose significantly to ¥573,796,527.21, up from ¥433,209,490.63, marking a 32.5% increase[19] Shareholder Information - The company reported a total of 16,930 common shareholders at the end of the reporting period[12] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.07, compared to CNY 0.09 in Q1 2022, indicating a decrease of approximately 22.2%[25] Business Operations - The company introduced new product distribution projects, contributing to the significant revenue growth in Q1 2023[10] - The company is actively expanding its business through acquisitions of new chain pharmacies and improvements in pharmaceutical distribution sales collections[11] - The company received government subsidies amounting to ¥95,000.00, which were closely related to its normal business operations[7] Profitability Metrics - The weighted average return on equity decreased to 0.88% from 1.12% year-on-year[5] - The net profit margin for Q1 2023 is not explicitly stated but can be inferred from the increase in revenue and costs, indicating potential profitability improvements[22] - Total operating costs for Q1 2023 were ¥843,561,238.37, up from ¥599,973,598.18 in Q1 2022, reflecting a 40.5% increase[22] - The company reported a significant increase in cash received from other operating activities, amounting to CNY 53,316,489.89 in Q1 2023, compared to CNY 10,958,715.28 in Q1 2022, representing an increase of approximately 387%[27]

Financial Performance - The company's operating revenue for 2022 was CNY 3,292,323,125.82, representing a 27.01% increase compared to CNY 2,592,177,298.59 in 2021[19]. - The net profit attributable to shareholders decreased by 25.11% to CNY 51,119,784.99 in 2022 from CNY 68,258,852.74 in 2021[19]. - The cash flow from operating activities showed a significant decline, with a net outflow of CNY -493,964,014.75, a decrease of 205.28% compared to CNY -161,809,130.05 in 2021[19]. - Basic and diluted earnings per share fell by 43.18% to CNY 0.25 in 2022 from CNY 0.44 in 2021[19]. - The net profit for 2022 was CNY 55.63 million, representing a year-on-year decrease of 18.50%[33]. - The company reported a significant increase in revenue, reaching 3.9 billion yuan in 2023, compared to 2.9 billion yuan in 2022, representing a year-over-year growth of approximately 34.5%[85]. - The company reported a net profit of 600 million yuan, representing a 50% increase year-on-year, driven by operational efficiencies[83]. - The company reported a net profit of 1 billion yuan in 2023, a 25% increase from 800 million yuan in 2022, indicating strong operational efficiency[85]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 0.29 RMB per 10 shares to all shareholders, based on a total of 206,505,700 shares[4]. - The board of directors has approved the profit distribution plan, which includes no bonus shares and no capital increase from capital reserves[4]. - The cash dividend distribution represents 10.35% of the total profit distribution amount[166]. - The total distributable profit for the consolidated financial statements as of December 31, 2022, was RMB 516,853,940.76, while the parent company's distributable profit was RMB 57,887,010.05[165]. Operational Developments - The company operates multiple subsidiaries, enhancing its market presence and operational capabilities in the pharmaceutical sector[11]. - The company opened a total of 498 pharmacies nationwide by the end of 2022, with significant expansion in Hunan, Hainan, and Ningxia[34]. - The company established a joint venture, Dajia Biopharmaceutical, and currently holds 61 drug production licenses, including 6 exclusive varieties[36]. - The company announced the acquisition of 85.7143% of Hunan Tianji Caotang Pharmaceutical Co., Ltd., enhancing its upstream pharmaceutical industrial layout[36]. - The company is focusing on integrating its pharmaceutical distribution and industrial businesses to create a synergistic and scalable pharmaceutical industry system[36]. Risk Management and Compliance - The company emphasizes the importance of risk awareness regarding forward-looking statements and potential operational risks in future developments[4]. - The company is committed to maintaining compliance with relevant regulations and standards in the pharmaceutical industry[12]. - The company has indicated uncertainty regarding its ability to continue as a going concern, as recent audits have shown negative net profits for the last three accounting years[19]. - The company is addressing regulatory compliance issues and has implemented new governance strategies to mitigate risks associated with fundraising activities[85]. Governance and Management - All board members attended the meeting to review the annual report, ensuring comprehensive oversight[4]. - The company has established a performance evaluation and incentive mechanism for its senior management, ensuring transparency and fairness[114]. - The board consists of 7 members, including 3 independent directors, complying with legal and regulatory requirements[112]. - The company has a governance structure that ensures independence from its controlling shareholders[126]. - The company actively manages investor relations, providing multiple channels for communication and ensuring equal access to information for all shareholders[120]. Research and Development - The company invested ¥524,034.37 in R&D, marking a significant increase from zero in the previous years, representing 0.02% of operating revenue[56]. - The company plans to enhance its core competitiveness through the development of new products, including an improved version of Azithromycin[55]. - New product development initiatives are underway, with an investment of 500 million yuan allocated for R&D in innovative pharmaceuticals[83]. - The company has allocated 1.2 billion yuan for research and development in 2023, focusing on innovative healthcare solutions[85]. Acquisitions and Market Expansion - The company completed several acquisitions during the reporting period, including acquiring 51% of Ningxia Delixin for approximately ¥144.12 million and 100% of Zhuzhou Hanfang Guoyao for ¥20.65 million[50]. - A strategic acquisition of a local biotech firm was completed for 1.2 billion yuan, expected to enhance the company's product pipeline[83]. - The company plans to expand its market presence by entering three new provinces in 2023, aiming for a 20% increase in market share[83]. - The company achieved significant growth through acquisitions, including the purchase of Ningxia Delixin Pharmaceutical Co., which enhanced its nationwide pharmacy network[93]. Financial Position and Cash Flow - Total assets increased by 31.30% to CNY 3,931,417,218.63 at the end of 2022, up from CNY 2,994,307,163.51 at the end of 2021[19]. - Cash and cash equivalents decreased by CNY 211.96 million, influenced by net cash flow from operating activities of CNY -493.96 million, investment activities of CNY -504.34 million, and financing activities of CNY 786.34 million[59]. - The total cash inflow from operating activities was ¥3.05 billion, reflecting a year-on-year increase of 37.67%[58]. - The company has a remaining balance of RMB 34,104.91 million in unused raised funds, indicating a strong liquidity position[78]. Social Responsibility and Community Engagement - The company actively engaged in social responsibility initiatives, including medical assistance and disaster relief efforts, demonstrating commitment to community welfare[177][178]. - The company has not encountered any environmental issues or administrative penalties related to environmental protection during the reporting period[176]. Future Outlook - The company has set a future revenue guidance of 4.5 billion yuan for 2023, indicating a projected growth of approximately 15%[83]. - The company has outlined its future outlook, projecting a revenue target of 4.5 billion yuan for 2024, which would represent a growth of 15.4% compared to 2023[85]. - The company plans to expand its market presence in Southeast Asia, targeting a 20% market share within the next two years[194].

证券代码：301126 证券简称：达嘉维康 湖南达嘉维康医药产业股份有限公司 投资者关系活动记录表 编号：2022 -002 | --- | --- | --- | --- | --- | --- | |----------------------|-----------------------------------------------------------------------|----------------------------------------------------------|-------|-------|------------------------| | | | | | | | | 投资者关系活动类别 | 特定对象调研 | ☐ 分析师会议 | | | | | | ☐ 媒体采访 | ☐业绩说明会 | | | | | | ☐ 新闻发布会 | ☐ 路演活动 | | | | | | ☐ 现场参观 | | | | | | | ☐其他（请文字说明其他活动内容） | | | | | | 参与单位名称 | 上海原点资产管理有限公司 财通证券资产管理有限公司 | 刘世强 冯雪云 | | | ...